Roth Capital Downgrades VNUS Medical Technologies (VNUS) to Hold
More News related to VNUS
- Roth Capital Downgrades VNUS Medical Technologies (VNUS) to Hold
- William Blair Downgrades VNUS Medical (VNUS) to Market Perform
- Notable Mergers and Acquisitions of the Day 5/8: COV/VNUS
- Morning Movers 5/8: FTWR, RDNT, VNUS, AXL, FITB, LEAP Higher; DPTR, CROX, INAP, HUN, GNW Lower
- Covidien (COV) To Acquire VNUS Medical (VNUS) For $29/Share
Roth Capital downgrades VNUS Medical Technologies (Nasdaq: VNUS) from Buy to Hold. Price target $29.
To see more analyst ratings on VNUS Click Here.
VNUS Medical Technologies, Inc. develops, manufactures and licenses products used in the minimally invasive treatment of venous reflux disease, including disposable endovenous catheters and radio-frequency (RF) generators.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
